These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36975491)

  • 1. Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C
    Suzuki H; Tanaka T; Goto N; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Feb; 45(3):1875-1888. PubMed ID: 36975491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Novel Anti-CD44 Variant 7/8 Monoclonal Antibody, C
    Suzuki H; Ozawa K; Tanaka T; Kaneko MK; Kato Y
    Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C
    Kudo Y; Suzuki H; Tanaka T; Kaneko MK; Kato Y
    Antibodies (Basel); 2023 Apr; 12(2):. PubMed ID: 37218897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Anti-CD44 Variant 9 Monoclonal Antibody C
    Tawara M; Suzuki H; Goto N; Tanaka T; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Apr; 45(4):3658-3673. PubMed ID: 37185762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Anti-CD44 Variant 3 Monoclonal Antibody C
    Suzuki H; Kitamura K; Goto N; Ishikawa K; Ouchida T; Tanaka T; Kaneko MK; Kato Y
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody C
    Ejima R; Suzuki H; Tanaka T; Asano T; Kaneko MK; Kato Y
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C
    Ishikawa K; Suzuki H; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Jun; 45(7):5248-5262. PubMed ID: 37504249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas.
    Goto N; Suzuki H; Tanaka T; Asano T; Kaneko MK; Kato Y
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C
    Suzuki H; Goto N; Tanaka T; Ouchida T; Kaneko MK; Kato Y
    Antibodies (Basel); 2023 Jul; 12(3):. PubMed ID: 37489367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.
    Ishikawa K; Suzuki H; Ohishi T; Li G; Tanaka T; Kawada M; Ohkoshi A; Kaneko MK; Katori Y; Kato Y
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C
    Suzuki H; Tawara M; Hirayama A; Goto N; Tanaka T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2024 Jun; 43(3):85-89. PubMed ID: 38507669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C
    Yamada S; Itai S; Nakamura T; Yanaka M; Kaneko MK; Kato Y
    Biochem Biophys Rep; 2018 Jul; 14():64-68. PubMed ID: 29872736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C
    Asano T; Kaneko MK; Takei J; Tateyama N; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):156-161. PubMed ID: 34283655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C
    Takei J; Asano T; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Oct; 40(5):219-226. PubMed ID: 34678095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Novel Epitope Mapping System: RIEDL Insertion for Epitope Mapping Method.
    Asano T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):162-167. PubMed ID: 34424761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications.
    Li G; Suzuki H; Asano T; Tanaka T; Suzuki H; Kaneko MK; Kato Y
    Antibodies (Basel); 2022 Jun; 11(2):. PubMed ID: 35735360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of CD44 splice variants in formalin-fixed, paraffin-embedded specimens of human skin cancer.
    Dietrich A; Tanczos E; Vanscheidt W; Schöpf E; Simon JC
    J Cutan Pathol; 1997 Jan; 24(1):37-42. PubMed ID: 9027631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
    Takei J; Kaneko MK; Ohishi T; Hosono H; Nakamura T; Yanaka M; Sano M; Asano T; Sayama Y; Kawada M; Harada H; Kato Y
    Oncol Rep; 2020 Nov; 44(5):1949-1960. PubMed ID: 33000243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a sandwich enzyme-linked immunosorbent assay for the detection of CD44v3 using exon v3- and v6-specific monoclonal antibody pairs.
    Jeoung MH; Kim TK; Shim H; Lee S
    J Immunol Methods; 2016 Sep; 436():22-8. PubMed ID: 27288967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas.
    Tran TA; Kallakury BV; Sheehan CE; Ross JS
    Hum Pathol; 1997 Jul; 28(7):809-14. PubMed ID: 9224749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.